

# Anti-VEGF-A Humanized Antibody

CATALOG NO.: A2136-100 (100 µg)

**BACKGROUND DESCRIPTION:** The research-grade biosimilar antibody is a recombinant humanized IgG1 kappa monoclonal without an Fc fragment. It binds to the receptor-binding site of vascular endothelial growth factor A (VEGF-A) and inhibits binding with its receptors (VEGFR1 and VEGFR2). This prevents VEGF-mediated proliferation and migration of endothelial cells and angiogenesis. The original drug received FDA approval in 2006 for the treatment of wet age-related macular degeneration. The drug has also been approved by the FDA to treat macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

**ALTERNATE NAMES:** rhuFab V2, Fab-12 variant Y0317, RhuFab, vascular endothelial growth factor A, VEGFA

**ANTIBODY TYPE:** Monoclonal

**CONCENTRATION:** 1 mg/ml

**HOST/ISOTYPE:** Recombinant / IgG1, kappa

**SOURCE:** CHO cells

**IMMUNOGEN:** Human VEGF-A

**MOLECULAR WEIGHT:** 48 kDa

**PURIFICATION:** Protein A purified

**FORM:** Liquid

**FORMULATION:** In PBS, pH 7.5

**SPECIES REACTIVITY:** Human

**STORAGE CONDITIONS:** Store at -80°C

**APPLICATIONS AND USAGE:** In vitro studies

**This information is only intended as a guide. The optimal dilutions must be determined by the user**

## RELATED PRODUCTS:

Anti-VEGF (Bevacizumab), Humanized Antibody (A1045)  
 Anti-IL-6 receptor (Tocilizumab), Human IgG1 Antibody (A1447)  
 Anti-PD-1 (Camrelizumab) humanized Antibody (A2132)  
 Anti-PD-1 (Pembrolizumab), Humanized Antibody (A1306)  
 Anti-IL-6R $\alpha$  (Sarilumab), Human IgG1 Antibody (A2133)

**FOR RESEARCH USE ONLY! Not to be used on humans.**